PDI Wants To Help Small Pharma Develop Products In-House
This article was originally published in The Pink Sheet Daily
Contract sales provider wants to diversify into small pharma services as big pharma cuts back outsourced sales reps.
You may also be interested in...
Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.
The $30 mil. acquisition will diversify revenue and expand marketing capabilities, PDI says. Once the deal closes, the company will have over $90 mil. in cash to pursue additional acquisitions.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.